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Abstract
Background—Manufacturers provide free sample medications as a means to increase use of
branded medications. Sample use varies year-to-year as branded product patents expire and new
products come to market.
Objective—This study sought to describe the use of sample medications during 2009–2013 and
assess individual characteristics associated with sample use.
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Methods—Data from the 2009–2013 U.S. Medical Expenditure Panel Survey (MEPS) were
used. MEPS asks participants whether they received each medication they are taking as a sample.
The top 10 medications and medication classes used each year by volume were identified as well
as the proportion of people who used at least one sample medication. The proportion of new
initiators of medications were also classified as the percent who received a sample for the specific
medication. Logistic regression was used to assess individual demographics, insurance, and
medication characteristics associated with use.
Results—Prevalence of sample use ranged from 9.3% in 2009 to 6.2% in 2013. The most widely
used sample medications included statins during 2009–2011, which changed to inhaled β-agonists
in 2012–2013, as atorvastatin became available as a generic. The overall volume of the top 10 free
sample medications decreased by one-third over this study period. In 2013, 12.6% of new insulin
analog users and 11.0% of new oral contraceptive users receive these medications through
samples. Regression analysis showed that U.S. Medicaid- and Medicare-insured persons were less
likely to use samples compared to those with private insurance.
Conclusions—Sample medication use has decreased as generic medications are becoming more
used in the U.S.
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Introduction
Free medication samples are widely disbursed to prescribers as a marketing tool for trade
name products. In 2005, the total value of medications provided was approximately $18
billion, with up to 20% of all Americans and nearly 50% of Medicare beneficiaries utilizing
samples annually.1,2 This practice is seen as pervasive by some medical associations and
patient advocacy groups but is typically viewed positively by prescribers and patients.3,4 As
implied, patients receive the medications for free and avoid immediate costs of the
medication at the point of care. Therapy is initiated immediately without a pharmacy visit
and the prescriber has the opportunity to provide medication counseling, which can be
important for certain dosage forms or devices.5
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Despite the perceived benefits, pharmaceutical companies intend the practice as a means to
increase use of branded medications. This can lead to increased use of more expensive
branded products, which increases costs to both patients and third-party payers if the
sampled medication is continued versus a suitable generic alternative.6–9 Further, use of
sample medications forgoes the typical process of prescribing and dispensing and removes
the medication experts – pharmacists – from their roles in screening for potential drug– drug
and drug–disease interactions and in providing medication counseling.10
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Medication sample use is difficult to analyze as the practice circumvents the process of
recording filled medications at the pharmacy or in insurance billing claims. Previous studies
have utilized the U.S. Medical Expenditure Panel Survey (MEPS) to investigate sample use
given that it provides a self-reported estimate of sample use in a nationally representative
weighted sample.11,12 These studies have looked at medication use through 2005 and have
identified individual characteristics associated with sample medication use. Medication
samples and the individuals utilizing them will vary by time as medication patent life expires
and because generic medication use has become more prevalent over the last decade. Thus,
this study sought to update the information regarding sample medication use in the U.S.
during the most recent five-year period available in MEPS (2009–2013). Medications used
as samples were identified and the individual characteristics associated with sample use in
the most recent year (2013) were also explored.

Methods
Data sources
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MEPS data were used to estimate the scope of free sample use and to characterize the
typical user. MEPS data are de-identified and publicly available and contain information on
patient demographics, sources of payment, medical service and pharmaceutical medication
utilization and expenditures. Due to the public and de-identified nature of these data, they
are exempt from an institutional review board approval process.
Study population and design
Data from years 2009–2013 were used to conduct a cross-sectional study that looked at the
disbursement of free medication samples in the U.S. over this time period. The most recent
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year available, 2013, was used to evaluate the individual characteristics of sample users.
There were no exclusions applied to the study sample.
Sample prescription medication use
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MEPS provided “Prescribed Medicines” files that contain information on prescription
medication use. Survey respondents are first asked about the medications they use and if
they received any of these medications as free samples. Any patient that identified at least
one of their medications as a free sample was considered a sample user for the study.
Patients are also asked to identify if they are a new user of a particular medication for the
respective year. The “Prescribed Medicines” file includes medication information for each
person and Generic Product Identifier (GPI) codes (Medi-Span, Indianapolis, IN) were used
to identify medications including all formulations for each medication. Using weights from
expenditure files provided by MEPS, the top 10 classes of medications and top 10
medications for each year of the data from 2009 to 2013 by volume were determined as well
as the percent of the population using sample medications each year. Additionally, for new
users of any medications in each year, the percent of patients receiving free sample for that
particular medication in the given year was reported.
Sample users characteristics in 2013
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MEPS 2013 “Full Year Consolidated” files contained demographic information on the
respondents. Race and ethnicity were combined into a single variable with the following
categories: Hispanics, non-Hispanic Whites, non-Hispanic Blacks and non-Hispanics that
belonged to other races. A new medical insurance indicator was created from variables
available in the data, and it consisted of the following insurance provider categories: Private,
Medicaid, Medicare (dual eligibles were classified in the Medicaid group), other public
insurance, and uninsured. Additionally, an indicator for prescription medication insurance
was included. Educational status was collapsed into two levels: lower than high school, and
at least high school level. Family income, as a percentage of the annual Federal Poverty
Limit (FPL), was classified for income <100% of FPL, ≥100 and <125% of FPL, ≥125%
and <200% of FPL, ≥200% and <400% of FPL, ≥400% of FPL. Geographic region was
based on U.S. Census regions. The total number of prescription medications used by each
individual in 2013 was also calculated.
Statistical analyses
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All statistical analyses were conducted using SAS 9.4 (Cary, North Carolina). SAS survey
commands were utilized to incorporate survey weights provided by MEPS; this allows the
generalization of results to represent the national population based on race, gender, age, and
geographic factors. Weighted counts and frequencies are reported for patient characteristics
for the year 2013. Chi-square tests were used to compare across categorical variables. A
multiple logistic regression model was performed to identify factors associated with the
receipt of any sample medications for 2013. This model included patient demographics,
access to care variables, and the count of total prescription medications. Odds ratios and
95% CI are reported. The significance level for the study was set at α < 0.05.
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Results
Medications used as samples
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Over the time period 2009–2013, prevalence of sample medication use decreased in the U.S.
from 9.3% in 2009 to 6.2% in 2013. Table 1 shows the top 10 individual medications and
medication classes used as samples by volume. During 2009–2011, HMG Co-A reductase
inhibitors (“statins”) were the most widely used sample medications, with a volume of
roughly 1.3 million samples each year. This group consisted mostly of rosuvastatin and
atorvastatin. Statins were supplanted by inhaled β-agonists, as atorvastatin lost patent
protection heading into 2012. Some medications widely available as generics but with
branded versions were in the top 10 in 2013, such as levothyroxine. Other highly used free
sample medication classes in 2013 included non-steroid anti-inflammatory drugs (NSAIDs),
proton pump inhibitors (PPIs), insulin analogs, and oral contraceptives. The total volume of
samples utilized in the top 10 medication classes decreased by over one-third between 2009
and 2013 (9 million to 6 million). For those under 18 years of age, asthma medications were
the highest utilized classes. For non-elderly adults, more variation was present with inhaled
β-agonists, anti-depressants, and statins being highly used, among others. For elderly
individuals, inhaled β-agonists (±steroids), statins, and β-blockers (oral and ophthalmic)
were highly utilized.
Table 2 shows the percent of people who were new initiators of each medication class who
used a sample for that class. For example, in 2009, 5.2% of statin initiators used a statin
sample while in 2013 only 2.8% did. In 2013, the highest initiators using samples were
among insulin users (12.6%), selective norepinephrine reuptake inhibitors (SNRIs; 13.9%),
and oral contraceptives (11.0%).
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Characteristics of free sample users
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Characteristics of samples users and non-users in 2013 are summarized in Table 3. The total
weighted sample represented nearly 180 million people in the U.S. who filled a prescription
medication. Table 4 shows the adjusted comparisons of users and non-users with adjusted
odds ratios (aOR) and 95% confidence intervals (CI). Gender, age, race, prescription drug
coverage, family income, and region were all non-significant predictors of sample use.
Those with Medicaid (aOR = 0.63, 95% CI 0.43–0.92) or Medicare (aOR = 0.56, 95% CI
0.34–0.95) insurance were less likely to use samples compared to those with private
insurance. Other public insurance and uninsured status was not associated with sample use
compared to the ‘Private’ reference group. Those with high school or higher education had
17–98% higher odds of being sample users compared to those with less than a high school
education. Also, for each additional prescription medication filled, the odds of sample used
increased by roughly 1–2%. The c-statistic for the model was 0.649, showing low model
discriminatory power for sample users.

Discussion
Year-to-year variability was observed in the medications sampled, which is associated with
patent expiry and new medications coming onto the market throughout the time period.
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Thus, the characteristics of free sample users are likely to change as new disease states are
treated by these sampled medications. Also observed was an overall decrease in sample use
as measured by the prevalence of sample users as well as the total volume of sample use.
This is attributed to the increase in generic utilization (85% of all prescriptions by volume)
overall in the U.S. as the number of block-bluster branded products have decreased.13
Despite decreasing prevalence, sample medications have a tremendous economic impact7,14
and can also influence research on products available through samples.15
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Sample medications are provided as a means of pharmaceutical marketing of branded
products, even when direct (i.e. same chemical entity) or therapeutic (i.e. same therapeutic
class) substitutes exist.7 While the practice has been defended as a means to provide
medications to those without insurance,16 this does not appear to be the case in this study or
in previous literature,11,12 and is counterintuitive, as uninsured individuals have fewer means
to attain branded products once the sample supply is extinguished. Cost implications
associated with this practice can impact individual out-of-pocket spending as well as thirdparty payer costs. This is especially concerning when low-cost generic programs are widely
prevalent and provide access to affordable medications regardless of insurance.17,18
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A study by Duru et al investigated the potential cost savings associated with both direct and
therapeutic substitution among diabetic patients with Medicare Part D coverage.7 They
found that direct substitution would save approximately $150 dollars per person and
therapeutic substitution would save $400 per person. Among the top ten medications in
2013, only levothyroxine was available as a generic. However, this is also an example where
substitution may not necessarily confer equivalence, as levothyroxine products have been
shown to vary in their bioavailability.19,20 Other examples include warfarin, estrogens, and
anticonvulants, which were also in the top 20 of all free sample drugs (data not shown).21
This further highlights the marketing strategy of free sample medications, as a patient could
not necessarily move from the sample branded product to a generic version without a
potential dose adjustment. Therapeutic substitution implies equivalence within a class,
which is arguable for a number of the Top 10 sampled classes including statins, NSAIDs,
PPIs, and SNRIs.22
Limitations
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This study is subject to some limitations. Primarily, sample use is self-reported by MEPS
participants who could misunderstand the question or have recall bias, although participants
are led through the survey by trained personnel. Other important medications by
expenditures, such as self-injected biologics, were also observed but not reportable due to
low sample sizes. The a priori objectives of this study were also to investigate individual
access to care characteristics as well as provider characteristics that were may be predictive
of sample use. However, a high number of missing responses were observed, limiting the
usefulness of these variables. Further, the adjusted model showed low discriminatory power
for sample users. This suggests that other individual characteristics, or prescriber
characteristics, may be predictive of sample use other than those variables included here.
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Conclusion
In the United States, 6.2% of prescription medication users used a free sample medication.
The types of medications used as samples changes annually as medications patent life
expires or new medications enter the market. Sample medications have tremendous cost
implications, especially when direct or therapeutic generic substitutes exist.
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Received at least one sample medications

Author Manuscript

Characteristics of sample users and non-users in 2013

49,696,269

158,704,468

18,03,5458

13,37,4713

4,58,6131

5,63,9400

2,254,5332

105,103,285

5,199,301

7,016,792

19,696,885

23,097,766

122,954,217

16,219,118

21,442,940

75,677,991

31,884,446

32,740,466

99,199,179

78,765,783

177,964,962

N

95.1

93.9

92.1

91.9

94.5

92.1

96.2

93.9

94.4

94.3

94.3

94.3

93.6

91.3

92.3

92.8

95.5

96.8

93.5

94.2

93.8

Row %

27.9

89.2

10.1

7.5

2.6

3.2

12.7

59.1

2.9

3.9

11.1

13.0

69.1

9.1

12.0

42.5

17.9

18.4

55.7

44.3

100

Column %

Did not receive any sample medication

Author Manuscript
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3,323,661
4,415,355

≥200 and < 400% of FPL
≥400% of FPL

5.1

2,100,639

16.9

P < 0.0001. =

**

P < 0.05;

*

FPL = Federal poverty limit; IQR interquartile range.

Number of prescriptions per person

Median

4,949,091

South
West

7.0

2,555,770

Midwest

6.5–38

IQR

6.0

2,138,492

6.4

5.9

6.0

7.6

7.0

5.8

3.2

7.1

Row %

Northeast

Region

627,291
1,917,262

≥125 and < 200% of FPL

1,479,221

405,545

8,820,674

≥100 and < 125% of FPL

<100% of FPL

Poverty status

Status missing

At least high school and higher

Author Manuscript
N

17.9

42.1

21.7

18.2

37.5

28.3

16.3

5.3

12.6

3.4

75.0

Column %

6.9

Median

38,789,974

66,143,817

40,241,534

31,531,686

70,407,643

51,736,455

23,434,432

8,304,644

24,081,788

12,292,976

115,975,717

N

1.8–19.7

IQR

94.9

93.0

94.0

93.6

94.1

94.0

92.4

93.0

94.2

96.8

92.9

Row %

21.8

37.2

22.6

17.7

39.6

29.1

13.2

4.7

13.5

6.9

65.2

Column %

Did not receive any sample medication

Author Manuscript

Received at least one sample medications

Brown et al.
Page 11

Author Manuscript

Res Social Adm Pharm. Author manuscript; available in PMC 2017 December 20.

Brown et al.

Page 12

Table 4

Author Manuscript

Results of multiple logistic regression predicting use of sample medications in 2013
Adjusted odds ratio

95% CI

P-value

Male

Ref.

Ref.

Ref.

Female

1.14

0.96, 1.36

0.1481

Less than 18 years

Ref.

Ref.

Ref.

18–34 years

0.81

0.50, 1.30

0.3835

35–64 years

1.10

0.73, 1.68

0.6453

65–74 years

1.16

0.72, 1.87

0.5504

75 years and above

1.27

0.73, 2.22

0.3918

non-Hispanic Whites

Ref.

Ref.

Ref.

Hispanics

1.19

0.94, 1.51

0.1428

non-Hispanic Blacks

0.89

0.73, 1.10

0.2958

Asians

1.15

0.77, 1.72

0.4864

Others

0.92

0.53, 1.58

0.7527

Private insurance

Ref.

Ref.

Ref.

Medicaid

0.63

0.43, 0.92

0.0155

Medicare

0.56

0.34, 0.95

0.0303

Other public insurance

0.88

0.52, 1.49

0.6205

Uninsured

1.19

0.80, 1.77

0.3909

Gender

Age categories

Race

Author Manuscript

Medical insurance coverage

Prescription drug insurance coverage

Author Manuscript
Author Manuscript

No

Ref.

Ref.

Ref.

Yes

0.74

0.52, 1.03

0.0759

Less than high school

Ref.

Ref.

Ref.

At least high school and higher

1.52

1.17, 1.98

0.0021

Status missing

1.03

0.62, 1.72

0.9089

<100% of FPL

Ref.

Ref.

Ref.

≥100 and <125% of FPL

1.00

0.68, 1.47

0.9876

≥125 and <200% of FPL

1.07

0.74, 1.55

0.7291

≥200 and <400% of FPL

0.81

0.56, 1.17

0.2656

≥400% of FPL

0.83

0.58, 1.17

0.2847

Northeast

Ref.

Ref.

Ref.

Midwest

0.98

0.69, 1.41

0.9261

South

1.18

0.87, 1.62

0.2898

West

0.82

0.58, 1.18

0.2873

Educational status

Poverty status (family income)

Region
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Number of prescriptions

Adjusted odds ratio

95% CI

P-value

1.02

1.01, 1.02

<0.0001

Author Manuscript

FPL = federal poverty limit; CI = confidence interval.
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Author Manuscript
Author Manuscript
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